Pancreatic Cancer Research

ResearcherIndiana University HealthActive in the last 2 years

Xiaoling Zhong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9458-5382; OpenAlex author ID A5080661780. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 8

  1. Transcriptome and microRNAome profiling of human skeletal muscle in pancreatic cancer cachexia First author DOI 10.1101/2025.09.02.25334959↗
  2. Gemcitabine plus nab-paclitaxel preserves skeletal and cardiac mass and function in a murine model of pancreatic cancer cachexia Co-author DOI 10.1101/2023.04.15.536434↗
  3. Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin. Co-author DOI 10.1002/jcsm.12998↗
  4. Profiling of Adipose and Skeletal Muscle in Human Pancreatic Cancer Cachexia Reveals Distinct Gene Profiles with Convergent Pathways. First author DOI 10.3390/cancers13081975↗
  5. Global targetome analysis reveals critical role of miR-29a in pancreatic stellate cell mediated regulation of PDAC tumor microenvironment. Co-author DOI 10.1186/s12885-020-07135-2↗
  6. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy. Co-author DOI 10.1002/jcsm.12461↗
  7. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2016-311585↗
  8. Anti-IL-6 and PD-L1 antibody combination therapy reduces tumor progression in murine models of pancreatic cancer Co-author DOI 10.1186/2051-1426-3-s2-p366↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Teresa A Zimmers · 7 shared papers, 2015–2025 · strength 0.84
  2. Ashok Narasimhan · 4 shared papers, 2021–2025 · strength 0.65
  3. Brittany R. Counts · 2 shared papers, 2023–2025 · strength 0.40
  4. Safi Shahda · 3 shared papers, 2019–2022 · strength 0.33
  5. Yunlong Liu · 3 shared papers, 2019–2022 · strength 0.33
  6. Michael Garrett House · 2 shared papers, 2019–2021 · strength 0.18
  7. Nicholas Joseph Zyromski · 2 shared papers, 2019–2021 · strength 0.18
  8. Eugene P. Ceppa · 2 shared papers, 2019–2021 · strength 0.18
  9. Christian Max Schmidt · 2 shared papers, 2019–2021 · strength 0.18
  10. Daenique H. A. Jengelley · 1 shared paper, 2023 · strength 0.14
  11. Melissa L. Fishel · 1 shared paper, 2023 · strength 0.14
  12. Joseph E. Rupert · 1 shared paper, 2023 · strength 0.14
  13. Mark R. Kelley · 1 shared paper, 2023 · strength 0.14
  14. Shatovisha Dey · 1 shared paper, 2020 · strength 0.11
  15. Janaiah Kota · 1 shared paper, 2020 · strength 0.11
  16. Mark Bloomston · 2 shared papers, 2015–2018 · strength 0.11
  17. Thomas Ludwig · 2 shared papers, 2015–2018 · strength 0.11
  18. Thomas A. Mace · 2 shared papers, 2015–2018 · strength 0.11
  19. Tanios Bekaii‐Saab · 2 shared papers, 2015–2018 · strength 0.11
  20. Gregory B. Lesinski · 2 shared papers, 2015–2018 · strength 0.11
  21. Jason Robert Pitarresi · 2 shared papers, 2015–2018 · strength 0.11
  22. Michael C. Ostrowski · 2 shared papers, 2015–2018 · strength 0.11
  23. Joshua K. Kays · 1 shared paper, 2021 · strength 0.10
  24. Lianbo Yu · 1 shared paper, 2018 · strength 0.07
  25. Zobeida Cruz‐Monserrate · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.